The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-11 2022 | The safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia
Mazyar Shadman, MD, MPH, Fred Hutchinson Cancer Research Center, Seattle, WA, shares some insights into the safety and efficacy of MB-106 for the treatment of Waldenström’s macroglobulinemia (WM), and ongoing studies evaluating this novel CAR-T construct. This interview took place at the 11th International Workshop on Waldenström’s Macroglobulinemia (IWWM-11), held in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
